目的观察在万托林联合喘可治雾化吸入治疗的基础上加用孟鲁司特钠治疗小儿咳嗽变异性哮喘的临床疗效。方法将100例咳嗽变异性哮喘患儿随机分为观察组和对照组各50例。2组均给予抗感染,止咳解痉等对症治疗;对照组给予万托林(吸入用沙丁胺醇溶液)联合喘可治注射液雾化吸入治疗;观察组在对照组基础上加用孟鲁司特钠口服治疗。比较2组临床疗效,并观察2组患儿咳嗽消失时间、哮鸣音消失时间以及哮喘持续时间。结果观察组患儿治疗总有效率为94%高于对照组的76%(P<0.05);观察组患者咳嗽消失时间、哮鸣音消失时间以及哮喘持续时间均短于对照组(P<0.05)。结论在万托林联合喘可治雾化吸入治疗的基础上加用孟鲁司特钠口服治疗,可明显提高临床疗效,缩短症状改善时间,值得临床推广应用。 Objective To observe the clinical efficacy of montelukast sodium in the treatment of pediatric cough variant asthma on the basis of combination of wantroplin and chuankezhi. Methods 100 cases of cough variant asthma children were randomly divided into observation group and control group of 50 cases. 2 groups were given symptomatic treatment of anti-infective, cough, antispasmodic and other symptomatic treatment; the control group was given vettorin (inhalation of salbutamol solution) combined with asthma treatment can be injected atomization inhalation therapy; observation group on the basis of the control group plus montelukast Sodium oral treatment. The clinical efficacy of the two groups were compared. The cough disappear time, wheezing disappearance time and duration of asthma were observed in two groups. Results The total effective rate of observation group was 94% higher than 76% of control group (P <0.05). The disappearance time of cough, wheezing disappearance time and duration of asthma in observation group were shorter than those in control group (P <0.05 ). Conclusion Wantelin combined with asthma inhalation treatment of asthma treatment based on the addition of montelukast sodium oral treatment can significantly improve clinical efficacy and shorten the time to improve symptoms worthy of clinical application.